A number of somatic mutations, or alterations of epigenetic regulation that activates the KEAP1-NRF2 pathway, have been reported in several human malignancies such as non-small cell lung carcinoma (NSCLC), and cancers of the skin and esophagus [4,5]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.